StockData
Kiniksa Pharmaceuticals International, plc logo

Kiniksa Pharmaceuticals International, plc (KNSA) shareholders

KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30469% above fair value
$95.11+0.88 (+0.93%)

Close on Nov 17, 2026Market cap $14.95BP/E 73.2Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
29.9%
47M of 157M shares
Institutional holders
267
72 new, 26 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
0 buys · 87 sales
Net sold $121.66M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Abigail P. Johnson
Joint filing with FMR LLC (14.80%)
6,787,70014.80%13G (passive) amendmentMar 31, 2026
FMR LLC
Joint filing with Abigail P. Johnson (10.60%)
4,854,35410.60%13G (passive)Feb 27, 2026
Rubric Capital Management LP
Joint filing with David Rosen (7.37%)
3,328,6537.37%13G (passive) amendmentDec 31, 2025
Felix J. Baker
Joint filing with Julian C. Baker (7.00%), Baker Bros. Advisors LP (6.90%) and 1 more
3,253,3417.00%13D (active) amendmentMay 21, 2026
BlackRock, Inc.2,534,7895.50%13G (passive)Jun 30, 2026
Kevin Tang
Joint filing with Tang Capital Management, LLC (5.20%)
2,178,6095.20%13G (passive)Mar 28, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of KNSAValueChange% of portfolio
FMR LLC6,971,3614.44%$445.82M+147,6610.02%
Rubric Capital Management LP3,999,8002.55%$255.79M+249,8002.35%
Baker Bros. Advisors LP2,834,6431.80%$181.28M+8,3970.91%
BlackRock, Inc.2,739,6151.74%$175.20M+2,252,8780.00%
Tang Capital Management LLC2,259,8891.44%$144.52M–6.56%
Vanguard Portfolio Management LLC1,911,3351.22%$122.23M+145,0670.01%
Vanguard Capital Management LLC1,360,8400.87%$87.03M+27,7470.00%
Morgan Stanley1,011,1430.64%$64.66M+13,3570.00%
Arrowstreet Capital, Limited Partnership957,5140.61%$61.23M+64,8480.03%
Spruce Street Capital LP918,0700.58%$58.71M+157,00711.52%
Dimensional Fund Advisors LP874,7860.56%$55.94M+62,8640.01%
Invesco Ltd.772,8060.49%$49.42M+745,1500.00%
Driehaus Capital Management LLC718,1990.46%$45.93M+106,8010.27%
State Street Corp704,1940.45%$45.03M+627,5610.00%
Acadian Asset Management LLC679,0830.43%$43.41M−657,2300.05%
Point72 Asset Management, L.P.659,4930.42%$42.17M+18,5350.05%
Rice Hall James & Associates, LLC624,9280.40%$39.96M+16,5121.95%
Pictet Asset Management Holding SA608,6500.39%$38.92M−14,6380.04%
Geode Capital Management, LLC604,1800.38%$38.63M+559,8600.00%
Jupiter Topco LLC586,1770.37%$37.47MNew0.02%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202626747M29.9%72 / 8681 / 269M7M
Q1 202622645M28.9%40 / 7684 / 3413M8M
Q4 202522343M27.3%42 / 7870 / 177M4M
Q3 202520241M26.1%47 / 6069 / 326M5M
Q2 202518740M25.4%48 / 6561 / 339M9M
Q1 202517440M25.4%36 / 5956 / 189M7M
Q4 202415839M24.8%19 / 6158 / 343M4M
Q3 202417440M25.3%62 / 5342 / 1514M5M
Q2 202412835M22.4%128 / 00 / 035M0M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Sanj K. PatelCHAIRMAN & CEO, Director1,602,8031.02%Nov 6, 2026
John F. PaoliniCHIEF MEDICAL OFFICER114,0480.07%Nov 17, 2026
Michael R. MegnaCHIEF ACCOUNTING OFFICER12,6970.01%Nov 12, 2026
Ross MoatCHIEF OPERATING OFFICER10,2940.01%Nov 3, 2026
Mark RagosaCHIEF FINANCIAL OFFICER20,8540.01%Nov 3, 2026
Dhiraj H. MalkaniCHIEF STRATEGY OFFICER––Jul 6, 2026
Eben TessariCHIEF STRATEGY OFFICER23,9760.02%Apr 8, 2026
Barry D. QuartDirector12,7450.01%Aug 21, 2026
Richard S. LevyDirector22,3590.01%Aug 4, 2026
G. Bradley ColeDirector11,6720.01%Jul 31, 2026
Bros. Advisors (GP) LLC BakerDirector123,8200.08%Jun 2, 2026
Brothers Life Sciences LP BakerDirector2,745,2591.75%Jun 2, 2026
Felix BakerDirector––Jun 2, 2026
Julian BakerDirector158,1170.10%Jun 2, 2026
Bros. Advisors Lp BakerDirector––Jun 2, 2026
Kimberly J. PopovitsDirector15,3450.01%Jun 2, 2026
Thomas MalleyDirector87,3120.06%Jun 2, 2026
Tracey L. McCainDirector15,3450.01%Jun 2, 2026
667, L.P.Director132,5660.08%Jun 2, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
John F. Paolini
CHIEF MEDICAL OFFICER
Nov 13, 2026Option exercise+2,595$15.52$40.27K114,048
John F. Paolini
CHIEF MEDICAL OFFICER
Nov 13, 2026Option exercise+3,144$12.97$40.78K111,453
John F. Paolini
CHIEF MEDICAL OFFICER
Nov 13, 2026Option exercise+3,723$11.97$44.56K108,309
John F. Paolini
CHIEF MEDICAL OFFICER
Nov 13, 2026Option exercise+4,994$11.10$55.43K104,586
John F. Paolini
CHIEF MEDICAL OFFICER
Nov 13, 2026Option exercise+29,670$10.36$307.38K99,592
Michael R. Megna
CHIEF ACCOUNTING OFFICER
Nov 9, 2026Sale(10b5-1 plan)−11,280$98.54$1.11M12,697
Michael R. Megna
CHIEF ACCOUNTING OFFICER
Nov 9, 2026Option exercise+11,280$17.76$200.33K23,977
Sanj K. Patel
CHAIRMAN & CEO, Director
Nov 4, 2026Sale(10b5-1 plan)−26,918$96.05$2.59M774,500
Sanj K. Patel
CHAIRMAN & CEO, Director
Nov 4, 2026Sale(10b5-1 plan)−29,845$95.48$2.85M801,418
Sanj K. Patel
CHAIRMAN & CEO, Director
Nov 4, 2026Sale(10b5-1 plan)−81,742$94.20$7.70M831,263
Sanj K. Patel
CHAIRMAN & CEO, Director
Nov 4, 2026Sale(10b5-1 plan)−11,335$93.54$1.06M913,005
Sanj K. Patel
CHAIRMAN & CEO, Director
Nov 4, 2026Sale(10b5-1 plan)−1,460$92.35$134.83K924,340
Sanj K. Patel
CHAIRMAN & CEO, Director
Nov 4, 2026Option exercise+145,763$17.92$2.61M925,800
Sanj K. Patel
CHAIRMAN & CEO, Director
Nov 3, 2026Sale(10b5-1 plan)−4,584$94.25$432.04K780,037
Sanj K. Patel
CHAIRMAN & CEO, Director
Nov 3, 2026Sale(10b5-1 plan)−145,708$93.53$13.63M784,621
Sanj K. Patel
CHAIRMAN & CEO, Director
Nov 3, 2026Sale(10b5-1 plan)−68,664$92.70$6.37M930,329
Sanj K. Patel
CHAIRMAN & CEO, Director
Nov 3, 2026Sale(10b5-1 plan)−1,214$90.77$110.19K998,993
Sanj K. Patel
CHAIRMAN & CEO, Director
Nov 3, 2026Option exercise+41,237$17.92$738.97K1,000,207
Sanj K. Patel
CHAIRMAN & CEO, Director
Nov 3, 2026Option exercise+89,089$8.83$786.66K958,970
Ross Moat
CHIEF OPERATING OFFICER
Nov 2, 2026Sale(10b5-1 plan)−722$94.05$67.90K10,294
Ross Moat
CHIEF OPERATING OFFICER
Nov 2, 2026Sale(10b5-1 plan)−11,642$93.15$1.08M11,016
Ross Moat
CHIEF OPERATING OFFICER
Nov 2, 2026Sale(10b5-1 plan)−8,932$92.05$822.19K22,658
Ross Moat
CHIEF OPERATING OFFICER
Nov 2, 2026Sale(10b5-1 plan)−6,681$91.23$609.51K31,590
Ross Moat
CHIEF OPERATING OFFICER
Nov 2, 2026Option exercise+6,263$22.89$143.36K38,271
Ross Moat
CHIEF OPERATING OFFICER
Nov 2, 2026Option exercise+12,302$21.77$267.81K32,008
Ross Moat
CHIEF OPERATING OFFICER
Nov 2, 2026Option exercise+9,412$18.06$169.98K19,706
Mark Ragosa
CHIEF FINANCIAL OFFICER
Nov 2, 2026Sale(10b5-1 plan)−220$94.01$20.68K20,854
Mark Ragosa
CHIEF FINANCIAL OFFICER
Nov 2, 2026Sale(10b5-1 plan)−12,034$93.13$1.12M21,074
Mark Ragosa
CHIEF FINANCIAL OFFICER
Nov 2, 2026Sale(10b5-1 plan)−10,502$92.03$966.50K33,108
Mark Ragosa
CHIEF FINANCIAL OFFICER
Nov 2, 2026Sale(10b5-1 plan)−14,027$91.40$1.28M43,610
Mark Ragosa
CHIEF FINANCIAL OFFICER
Nov 2, 2026Option exercise+9,636$17.76$171.14K57,637
Mark Ragosa
CHIEF FINANCIAL OFFICER
Nov 2, 2026Option exercise+12,123$11.97$145.11K48,001
Mark Ragosa
CHIEF FINANCIAL OFFICER
Nov 2, 2026Option exercise+5,388$11.10$59.81K35,878
Mark Ragosa
CHIEF FINANCIAL OFFICER
Nov 2, 2026Option exercise+9,636$10.76$103.68K30,490
John F. Paolini
CHIEF MEDICAL OFFICER
Nov 2, 2026Sale(10b5-1 plan)−704$94.09$66.24K69,922
John F. Paolini
CHIEF MEDICAL OFFICER
Nov 2, 2026Sale(10b5-1 plan)−16,810$93.42$1.57M70,626
John F. Paolini
CHIEF MEDICAL OFFICER
Nov 2, 2026Sale(10b5-1 plan)−899$92.37$83.04K87,436
John F. Paolini
CHIEF MEDICAL OFFICER
Nov 2, 2026Option exercise+11,958$17.92$214.29K88,335
John F. Paolini
CHIEF MEDICAL OFFICER
Nov 2, 2026Option exercise+6,455$30.93$199.65K76,377
Sanj K. Patel
CHAIRMAN & CEO, Director
Nov 2, 2026Sale(10b5-1 plan)−100$93.97$9.40K869,881
Sanj K. Patel
CHAIRMAN & CEO, Director
Nov 2, 2026Sale(10b5-1 plan)−26,781$93.06$2.49M869,981
Sanj K. Patel
CHAIRMAN & CEO, Director
Nov 2, 2026Sale(10b5-1 plan)−24,188$91.83$2.22M896,762
Sanj K. Patel
CHAIRMAN & CEO, Director
Nov 2, 2026Sale(10b5-1 plan)−38,364$91.03$3.49M920,950
Sanj K. Patel
CHAIRMAN & CEO, Director
Nov 2, 2026Option exercise+53,381$8.83$471.35K959,314
Ross Moat
CHIEF OPERATING OFFICER
Oct 30, 2026Sale(10b5-1 plan)−2,575$97.76$251.73K10,294
Ross Moat
CHIEF OPERATING OFFICER
Oct 30, 2026Sale(10b5-1 plan)−1,760$97.10$170.90K12,869
Ross Moat
CHIEF OPERATING OFFICER
Oct 30, 2026Sale(10b5-1 plan)−3,672$96.03$352.62K14,629
Ross Moat
CHIEF OPERATING OFFICER
Oct 30, 2026Sale(10b5-1 plan)−6,282$94.92$596.29K18,301
Ross Moat
CHIEF OPERATING OFFICER
Oct 30, 2026Sale(10b5-1 plan)−8,430$93.97$792.17K24,583
Ross Moat
CHIEF OPERATING OFFICER
Oct 30, 2026Sale(10b5-1 plan)−15,114$92.81$1.40M33,013
Ross Moat
CHIEF OPERATING OFFICER
Oct 30, 2026Sale(10b5-1 plan)−37,775$92.00$3.48M48,127
Ross Moat
CHIEF OPERATING OFFICER
Oct 30, 2026Option exercise+10,895$18.06$196.76K85,902
Ross Moat
CHIEF OPERATING OFFICER
Oct 30, 2026Option exercise+16,112$17.76$286.15K75,007
Ross Moat
CHIEF OPERATING OFFICER
Oct 30, 2026Option exercise+1,658$12.97$21.50K58,895
Ross Moat
CHIEF OPERATING OFFICER
Oct 30, 2026Option exercise+3,760$11.97$45.01K57,237
Ross Moat
CHIEF OPERATING OFFICER
Oct 30, 2026Option exercise+21,059$11.10$233.75K53,477
Ross Moat
CHIEF OPERATING OFFICER
Oct 30, 2026Option exercise+16,111$10.76$173.35K32,418
John F. Paolini
CHIEF MEDICAL OFFICER
Oct 30, 2026Sale(10b5-1 plan)−2,155$97.77$210.69K69,922
John F. Paolini
CHIEF MEDICAL OFFICER
Oct 30, 2026Sale(10b5-1 plan)−1,925$97.06$186.84K72,077
John F. Paolini
CHIEF MEDICAL OFFICER
Oct 30, 2026Sale(10b5-1 plan)−4,000$95.97$383.88K74,002

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
2.88%
4M shares short
Days to cover
3.9
At 1M shares a day
Change since last report
+14.1%
From 4M shares
Short volume, 20 days
43.8%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Kiniksa Pharmaceuticals International's stock actually held short. Settlement fails (shares not delivered on time) peaked at 9,617 shares on Sep 17, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Mark Ragosa
Officer
Nov 2, 202636,783$3.39MNov 2, 2026Employee Stock Option Exercise
Sanj K. Patel
Officer, Director
Oct 30, 2026553,794$51.57MOct 30, 2026Restricted Stock Lapse - see remarks
Ross Moat
Officer
Oct 30, 2026103,585$9.75MOct 30, 2026Restricted Stock Lapse
Michael R. Megna
Officer
Oct 30, 202647,540$4.56MOct 30, 2026Restricted Stock Lapse - See Remarks
John F. Paolini
Officer
Oct 30, 202696,000$8.93MOct 30, 2026Employee Stock Option Exercise - See Remarks
Michael R. Megna
Officer
Sep 3, 20264,600$369.38KSep 3, 2026Restricted Stock Lapse
G. Bradley Cole
Director
Jul 29, 20263,673$299.09KJul 29, 2026Restricted Stock Lapse
Eben Tessari
Former Affiliate
Jul 29, 202667,062$5.35MJul 29, 2026Employee Stock Option Exercise
John F. Paolini
Officer
May 1, 202658,424$3.14MMay 1, 2026Employee Stock Option Exercise
Sanj K. Patel
Officer, Director
Apr 28, 2026344,591$17.78MApr 28, 2026Employee Stock Option Exercise - See Remarks
Ross Moat
Officer
Apr 9, 20261,703$79.51KApr 9, 2026Restricted Stock Lapse
Michael R. Megna
Officer
Apr 9, 20266,625$309.32KApr 9, 2026Restricted Stock Lapse
Sanj K. Patel
Officer, Director
Apr 6, 2026219,591$10.98MApr 6, 2026Employee Stock Option Exercise - See Remarks
Barry D. Quart
Director
Apr 6, 202620,000$1.00MApr 6, 2026Employee Stock Option Exercise - see remarks
Ross Moat
Officer
Apr 6, 20262,367$114.99KApr 6, 2026Restricted Stock Lapse

See a number that looks wrong?